Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding

Radoslaw Wasiak, Anna Filonenko, David J. Vanness, Amy Law, Mark Jeddi, Kim U. Wittrup-Jensen, Donald E. Stull, Steven Siak, Jeffrey Jensen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: To quantify the change in work productivity and activities of daily living in North American women with heavy menstrual bleeding (HMB) treated with estradiol valerate/dienogest (E2V/DNG; Qlaira ®/Natazia®) compared to placebo. Methods: Women in the United States and Canada, aged 20-53 years with an objective diagnosis of HMB and no recognizable anatomical pathology, were treated with E 2V/DNG or placebo for seven cycles (196 days). Main outcome measures included work productivity (i.e., productivity while at work) and activities of daily living measured using a modified Work Productivity and Activity Impairment Questionnaire (mWPAI) on a Likert scale from 0 to 10 (higher values denote higher impairment levels). Results: In both countries, significant improvement was observed between baseline and end of treatment in work productivity and activities of daily living impairment. The improvements in work productivity and activities of daily living with E2V/DNG treatment relative to placebo ranged from 37.2% to 39.2% across both countries. Monthly gains due to E2V/DNG treatment (net of placebo improvement) associated with improvement in work productivity were estimated to be US$80.2 and Can$70.8 (US$58.5) and those associated with improvement in activities of daily living were estimated to be US$84.9 and Can$73.5 (US$60.7). Conclusions: E2V/DNG was shown to have a consistent positive impact on work productivity and activities of daily living in U.S. and Canadian women with HMB. In addition, these improvements in work productivity and activities of daily living were associated with a reduction in HMB-related monetary burden compared to the placebo group.

Original languageEnglish (US)
Pages (from-to)378-383
Number of pages6
JournalJournal of Women's Health
Volume22
Issue number4
DOIs
StatePublished - Apr 1 2013

Fingerprint

Activities of Daily Living
Hemorrhage
Placebos
estradiol valerate-dienogest
Canada
Therapeutics
Outcome Assessment (Health Care)
Pathology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding. / Wasiak, Radoslaw; Filonenko, Anna; Vanness, David J.; Law, Amy; Jeddi, Mark; Wittrup-Jensen, Kim U.; Stull, Donald E.; Siak, Steven; Jensen, Jeffrey.

In: Journal of Women's Health, Vol. 22, No. 4, 01.04.2013, p. 378-383.

Research output: Contribution to journalArticle

Wasiak, R, Filonenko, A, Vanness, DJ, Law, A, Jeddi, M, Wittrup-Jensen, KU, Stull, DE, Siak, S & Jensen, J 2013, 'Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding', Journal of Women's Health, vol. 22, no. 4, pp. 378-383. https://doi.org/10.1089/jwh.2012.3633
Wasiak, Radoslaw ; Filonenko, Anna ; Vanness, David J. ; Law, Amy ; Jeddi, Mark ; Wittrup-Jensen, Kim U. ; Stull, Donald E. ; Siak, Steven ; Jensen, Jeffrey. / Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding. In: Journal of Women's Health. 2013 ; Vol. 22, No. 4. pp. 378-383.
@article{5ecff807d65c4f79916e37ecf0862e8c,
title = "Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding",
abstract = "Objectives: To quantify the change in work productivity and activities of daily living in North American women with heavy menstrual bleeding (HMB) treated with estradiol valerate/dienogest (E2V/DNG; Qlaira {\circledR}/Natazia{\circledR}) compared to placebo. Methods: Women in the United States and Canada, aged 20-53 years with an objective diagnosis of HMB and no recognizable anatomical pathology, were treated with E 2V/DNG or placebo for seven cycles (196 days). Main outcome measures included work productivity (i.e., productivity while at work) and activities of daily living measured using a modified Work Productivity and Activity Impairment Questionnaire (mWPAI) on a Likert scale from 0 to 10 (higher values denote higher impairment levels). Results: In both countries, significant improvement was observed between baseline and end of treatment in work productivity and activities of daily living impairment. The improvements in work productivity and activities of daily living with E2V/DNG treatment relative to placebo ranged from 37.2{\%} to 39.2{\%} across both countries. Monthly gains due to E2V/DNG treatment (net of placebo improvement) associated with improvement in work productivity were estimated to be US$80.2 and Can$70.8 (US$58.5) and those associated with improvement in activities of daily living were estimated to be US$84.9 and Can$73.5 (US$60.7). Conclusions: E2V/DNG was shown to have a consistent positive impact on work productivity and activities of daily living in U.S. and Canadian women with HMB. In addition, these improvements in work productivity and activities of daily living were associated with a reduction in HMB-related monetary burden compared to the placebo group.",
author = "Radoslaw Wasiak and Anna Filonenko and Vanness, {David J.} and Amy Law and Mark Jeddi and Wittrup-Jensen, {Kim U.} and Stull, {Donald E.} and Steven Siak and Jeffrey Jensen",
year = "2013",
month = "4",
day = "1",
doi = "10.1089/jwh.2012.3633",
language = "English (US)",
volume = "22",
pages = "378--383",
journal = "Journal of Women's Health",
issn = "1540-9996",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding

AU - Wasiak, Radoslaw

AU - Filonenko, Anna

AU - Vanness, David J.

AU - Law, Amy

AU - Jeddi, Mark

AU - Wittrup-Jensen, Kim U.

AU - Stull, Donald E.

AU - Siak, Steven

AU - Jensen, Jeffrey

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Objectives: To quantify the change in work productivity and activities of daily living in North American women with heavy menstrual bleeding (HMB) treated with estradiol valerate/dienogest (E2V/DNG; Qlaira ®/Natazia®) compared to placebo. Methods: Women in the United States and Canada, aged 20-53 years with an objective diagnosis of HMB and no recognizable anatomical pathology, were treated with E 2V/DNG or placebo for seven cycles (196 days). Main outcome measures included work productivity (i.e., productivity while at work) and activities of daily living measured using a modified Work Productivity and Activity Impairment Questionnaire (mWPAI) on a Likert scale from 0 to 10 (higher values denote higher impairment levels). Results: In both countries, significant improvement was observed between baseline and end of treatment in work productivity and activities of daily living impairment. The improvements in work productivity and activities of daily living with E2V/DNG treatment relative to placebo ranged from 37.2% to 39.2% across both countries. Monthly gains due to E2V/DNG treatment (net of placebo improvement) associated with improvement in work productivity were estimated to be US$80.2 and Can$70.8 (US$58.5) and those associated with improvement in activities of daily living were estimated to be US$84.9 and Can$73.5 (US$60.7). Conclusions: E2V/DNG was shown to have a consistent positive impact on work productivity and activities of daily living in U.S. and Canadian women with HMB. In addition, these improvements in work productivity and activities of daily living were associated with a reduction in HMB-related monetary burden compared to the placebo group.

AB - Objectives: To quantify the change in work productivity and activities of daily living in North American women with heavy menstrual bleeding (HMB) treated with estradiol valerate/dienogest (E2V/DNG; Qlaira ®/Natazia®) compared to placebo. Methods: Women in the United States and Canada, aged 20-53 years with an objective diagnosis of HMB and no recognizable anatomical pathology, were treated with E 2V/DNG or placebo for seven cycles (196 days). Main outcome measures included work productivity (i.e., productivity while at work) and activities of daily living measured using a modified Work Productivity and Activity Impairment Questionnaire (mWPAI) on a Likert scale from 0 to 10 (higher values denote higher impairment levels). Results: In both countries, significant improvement was observed between baseline and end of treatment in work productivity and activities of daily living impairment. The improvements in work productivity and activities of daily living with E2V/DNG treatment relative to placebo ranged from 37.2% to 39.2% across both countries. Monthly gains due to E2V/DNG treatment (net of placebo improvement) associated with improvement in work productivity were estimated to be US$80.2 and Can$70.8 (US$58.5) and those associated with improvement in activities of daily living were estimated to be US$84.9 and Can$73.5 (US$60.7). Conclusions: E2V/DNG was shown to have a consistent positive impact on work productivity and activities of daily living in U.S. and Canadian women with HMB. In addition, these improvements in work productivity and activities of daily living were associated with a reduction in HMB-related monetary burden compared to the placebo group.

UR - http://www.scopus.com/inward/record.url?scp=84876245092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876245092&partnerID=8YFLogxK

U2 - 10.1089/jwh.2012.3633

DO - 10.1089/jwh.2012.3633

M3 - Article

C2 - 23586801

AN - SCOPUS:84876245092

VL - 22

SP - 378

EP - 383

JO - Journal of Women's Health

JF - Journal of Women's Health

SN - 1540-9996

IS - 4

ER -